1. Home
  2. EOLS vs CIVB Comparison

EOLS vs CIVB Comparison

Compare EOLS & CIVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EOLS
  • CIVB
  • Stock Information
  • Founded
  • EOLS 2012
  • CIVB 1884
  • Country
  • EOLS United States
  • CIVB United States
  • Employees
  • EOLS N/A
  • CIVB N/A
  • Industry
  • EOLS Biotechnology: Pharmaceutical Preparations
  • CIVB Major Banks
  • Sector
  • EOLS Health Care
  • CIVB Finance
  • Exchange
  • EOLS Nasdaq
  • CIVB Nasdaq
  • Market Cap
  • EOLS 493.5M
  • CIVB 466.9M
  • IPO Year
  • EOLS 2018
  • CIVB N/A
  • Fundamental
  • Price
  • EOLS $7.66
  • CIVB $21.02
  • Analyst Decision
  • EOLS Strong Buy
  • CIVB Buy
  • Analyst Count
  • EOLS 5
  • CIVB 5
  • Target Price
  • EOLS $21.25
  • CIVB $25.50
  • AVG Volume (30 Days)
  • EOLS 1.2M
  • CIVB 81.0K
  • Earning Date
  • EOLS 11-05-2025
  • CIVB 10-28-2025
  • Dividend Yield
  • EOLS N/A
  • CIVB 3.23%
  • EPS Growth
  • EOLS N/A
  • CIVB 18.46
  • EPS
  • EOLS N/A
  • CIVB 2.52
  • Revenue
  • EOLS $277,941,000.00
  • CIVB $157,428,000.00
  • Revenue This Year
  • EOLS $14.01
  • CIVB $17.30
  • Revenue Next Year
  • EOLS $29.46
  • CIVB $12.90
  • P/E Ratio
  • EOLS N/A
  • CIVB $8.33
  • Revenue Growth
  • EOLS 17.15
  • CIVB 7.00
  • 52 Week Low
  • EOLS $5.71
  • CIVB $16.24
  • 52 Week High
  • EOLS $17.82
  • CIVB $25.59
  • Technical
  • Relative Strength Index (RSI)
  • EOLS 50.21
  • CIVB 54.36
  • Support Level
  • EOLS $7.19
  • CIVB $20.64
  • Resistance Level
  • EOLS $7.67
  • CIVB $21.24
  • Average True Range (ATR)
  • EOLS 0.34
  • CIVB 0.48
  • MACD
  • EOLS 0.13
  • CIVB 0.14
  • Stochastic Oscillator
  • EOLS 79.29
  • CIVB 77.59

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

About CIVB Civista Bancshares Inc.

Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agriculture, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. Majority of its revenues are derived from the interest and fees gained on loans.

Share on Social Networks: